Cyclophosphamide
Navigation Links
Cyclophosphamide in Medical News
High-Dosage of Epirubicin and Cyclophosphamide may cause AML
Adjuvant chemotherapy with epirubicin and cyclophosphamide for early breast cancer// patients increased the risk of Acute myeloid leukemia or Myelodysplastic syndrome. Recent study published in Journal of clinical oncology reports that early breast cancer patients undergoing chemotherapy with ...... Cardiac toxicity may also occur at lower cumulative doses (400 mg/m2) in patients with prior mediastinal irradiation or who are receiving concurrent cyclophosphamide therapy Acute infusion-related reactions including, but not limited to, flushing, shortness of breath, facial swelling, headache, ...
Gene Can Dampen Chemo Drug Effectiveness
...sphamide, an agent used against breast tumors, blood cancers and other malignancies. The research is the first to show a mechanism and a biomarker for cyclophosphamide resistance. Although this is not good news for some patients, the findings have a silver lining: New tests may soon be developed to help doctors sc......arlier Stages The companies also announced today the initiation of an additional Phase III study of ofatumumab in combination with fludarabine and cyclophosphamide (FC) for patients with CLL when initial treatment no longer works (second-line treatment). The open-label study will randomize 352 patients to evaluat...
Hypertension & cholesterol medications present in water released into the St. Lawrence River
...reducing medication), enalapril (hypertension medication), methotrexate and cyclophosphamide (two products used in the treatment of certain cancers) have all been detec...because of the large quantities prescribed by physicians. "Methotrexate and cyclophosphamide are two products very often used to treat cancer and are more likely to be ...US Oncology Research Network Presents Clinical Studies at San Antonio Breast Cancer Symposium
...rial of adjuvant docetaxel/cyclophosphamde plus trastuzumab in HER2+ early stage breast cancer patients." -- Dr. Jones' study, "Docetexal plus cyclophosphamide is cost-effective compared to doxorubicin plus cyclophosphamide, based on an economic analysis of US Oncology Trial 9735: Additional rational to avoid...New therapy prevents dangerous side effect for lymphoma patients
...at The University of Texas M. D. Anderson Cancer Center report today at the 50th annual meeting of the American Society of Hematology. Pentostatin, cyclophosphamide and rituximab together are providing the same remission rate as other combinations but with minimal long-term bone marrow suppression, said study pres...Late-breaking data to be presented at the American Society of Hematology Annual Meeting
...regardless of previous treatment regimens." Rituximab, Fludarabine, and cyclophosphamide (R-FC) Prolongs Progression-Free Survival in Relapsed or Refractory Chronic...ix 28-day cycles of fludarabine (25 mg/m2 intravenously on days 1 to 3) and cyclophosphamide (250 mg/m2 intravenously on days 1 to 3) alone (FC) or in combination with ...Novel treatments show improvements in survival and response rates for leukemia and lymphoma
...py With Fludarabine, Cyclophosphamide, and Rituximab Versus Fludarabine and cyclophosphamide Improves Response Rates and Progression-Free Survival of Previously Untreat...ix 28-day cycles of fludarabine (25 mg/m2 intravenously on days 1 to 3) and cyclophosphamide (FC) (250 mg/m2 intravenously on days 1 to 3) alone or FCR (375 mg/m2 int...... Fludarabine, Cyclophosphamide, and Ritux i mab Versus Fludarabine and cyclophosphamide I m proves R e sponse Rates and Progression-Free Survival of Pr e ...x 28-day cycles of fludarabine (25 mg/m^2 intravenously on days 1 to 3) and cyclophosphamide (FC) (250 mg/m^2 intravenously on days 1 to 3) alone or FCR (375 mg/m^2 int...
Cyclophosphamide in Medical Technology
22 US Oncology Affiliated Physicians Participate in ASCO
Proceedings
HOUSTON, June 04, 2007 /PRNewswire/ -- A leading cancer
researcher affiliated with the US Oncology Research Network
presented findings from a randomized, multicenter phase III trial
that compared the disease-free survival (DFS) o...
... also occur at lower cumulative doses (400 mg/m2) in patients with prior mediastinal irradiation or who are receiving concurrent cyclophosphamide therapy * Acute infusion-related reactions including, but not limited to, flushing, shortness of breath, facial swelling, headache, chills...
...bine (X) is 11:45 hrs Cancer Group integrated into docetaxel (T) General 5-FU + epirubicin + cyclophosphamide Session 7 (CEF) adjuvant therapy for high-risk early breast cancer (BC): interim ana...
...th Del 17p In this analysis, researchers evaluated Campath in combination with the standard treatment regimen known as FCR (fludarabine, cyclophosphamide and rituximab) as front-line therapy to a high-risk group of CLL patients. Of the 60 patients intended for analysis in the CFAR group, 48 wer...
...a median of four cycles (range: 2-11 cycles), which were presented by Shaji Kumar, M.D., Mayo Clinic, showed: -- The maximum tolerated dose of cyclophosphamide in the VcDCR regimen was not reached. The recommended doses for the Phase II portion of the trial include 500 mg/m(2) of cyclophosphamide, the highest...
...less of previous treatment regimens." Rituximab, Fludarabine, and cyclophosphamide (R-FC) Prolongs Progression-Free Survival in Relapsed or Refractor...x 28-day cycles of fludarabine (25 mg/m^2 intravenously on days 1 to 3) and cyclophosphamide (250 mg/m^2 intravenously on days 1 to 3) alone (FC) or in combination with...
...eloma. The results showed the status of 28 evaluable patients, who received cyclophosphamide at 300 mg/m2 on days 1, 8, 15, 22, VELCADE at 1.3 mg/m2 on days 1, 4, 8 and...rough 18 for one cycle and on days 1 through 4 for cycles two through four. cyclophosphamide at 3 g/m2 and G-CSF were used to harvest stem cells. Patients were then con...
... also occur at lower cumulative doses (400 mg/m2) in patients with prior mediastinal irradiation or who are receiving concurrent cyclophosphamide therapy * Acute infusion-related reactions including, but not limited to, flushing, shortness of breath, facial swelling, headache, chills...
...bine (X) is 11:45 hrs Cancer Group integrated into docetaxel (T) General 5-FU + epirubicin + cyclophosphamide Session 7 (CEF) adjuvant therapy for high-risk early breast cancer (BC): interim ana...
...th Del 17p In this analysis, researchers evaluated Campath in combination with the standard treatment regimen known as FCR (fludarabine, cyclophosphamide and rituximab) as front-line therapy to a high-risk group of CLL patients. Of the 60 patients intended for analysis in the CFAR group, 48 wer...
New Study Shows PCR and FCR Have Significant Activity in B-cell Chronic Lymphocytic Leukemia
...omising results have been reported with the combination of fludarabine (F), cyclophosphamide (C), and rituximab (R) (FCR) by Keating and colleagues at the University o...Mayo Clinic and MSKCC trials, evaluated the combination of pentostatin (P), cyclophosphamide (C), and rituximab (R) (PCR); results suggested similar efficacy with less ......a median of four cycles (range: 2-11 cycles), which were presented by Shaji Kumar, M.D., Mayo Clinic, showed: -- The maximum tolerated dose of cyclophosphamide in the VcDCR regimen was not reached. The recommended doses for the Phase II portion of the trial include 500 mg/m(2) of cyclophosphamide, the highest...
...less of previous treatment regimens." Rituximab, Fludarabine, and cyclophosphamide (R-FC) Prolongs Progression-Free Survival in Relapsed or Refractor...x 28-day cycles of fludarabine (25 mg/m^2 intravenously on days 1 to 3) and cyclophosphamide (250 mg/m^2 intravenously on days 1 to 3) alone (FC) or in combination with...
The Leukemia & Lymphoma Society and Memgen Announce New Chronic Lymphocytic Leukemia Clinical Trial
... an immune-boosting molecule, ISF35 (Immune Stimulatory Factor 35), followed by three courses of rituximab plus the chemotherapy drugs fludarabine and cyclophosphamide (FCR). "This clinical study builds upon three previous trials already completed at M.D. Anderson and here at UCSD," said Januario E. Castro, ...Genmab A/S - Company Announcement: Recruitment Completed In Ofatumumab CLL Front Line Study
...nts in the Phase II study of ofatumumab in combination with fludarabine and cyclophosphamide to treat front line CLL. Genmab A/S (OMX: GEN) announced today it has com...II study of ofatumumab (HuMax-CD20 (R)) in combination with fludarabine and cyclophosphamide (FC) to treat chronic lymphocytic leukemia (CLL) in previously untreated pa......eloma. The results showed the status of 28 evaluable patients, who received cyclophosphamide at 300 mg/m2 on days 1, 8, 15, 22, VELCADE at 1.3 mg/m2 on days 1, 4, 8 and...rough 18 for one cycle and on days 1 through 4 for cycles two through four. cyclophosphamide at 3 g/m2 and G-CSF were used to harvest stem cells. Patients were then con...
Cyclophosphamide in Biological News
Hypertension and cholesterol medications present in water released into the St. Lawrence River
...reducing medication), enalapril (hypertension medication), methotrexate and cyclophosphamide (two products used in the treatment of certain cancers) have all been detec...because of the large quantities prescribed by physicians. "Methotrexate and cyclophosphamide are two products very often used to treat cancer and are more likely to be ...New chemotherapy combo produces side effects, but no extra efficacy, in early breast cancer patients
...has the effect of reducing patient compliance, so, given all these factors we would recommend staying with current standard treatments epirubicin and cyclophosphamide followed by a taxane, or TAC, another commonly used three-drug combination of docetaxel, doxorubicin and cyclophosphamide, said Professor von Minckwit...Oncolytics Biotech, Inc. announces publication of research
...and safety of various combinations of reovirus and cyclophosphamide in vivo. The paper, entitled cyclophosphamide Facilitates Antitumor Efficacy against Subcutaneou...ted the initiation of our combination REOLYSIN and cyclophosphamide clinical trial, recently approved by the U.K. heal...CSHL scientists identify and repress breast cancer stem cells in mouse tissue
... cancer has the potential to actually enrich the subpopulation of stem-like cells that serve as cancer progenitors. We found that administration of cyclophosphamide in our mouse cell sample had the effect of enriching for these cells, Hannon said, which suggests that we need to look carefully at these therapies in...Dealing deadly cancers a knockout punch
...in further detail in future preclinical work. Another presentation at the Arizona conference reported on the use of Reolysin plus the cancer drug cyclophosphamide in an animal model of melanoma. When treated with both agents, test animals experienced enhanced tumor regression compared with either agent alone, an...Botox could help target resistant tumors for treatment
...mulation of apoptosis (programmed cellular death) when compared by irradiation without Botox. The combination of Botox and the chemotherapeutic agent cyclophosphamide showed significantly stunted tumor growth after three days, as well. Since Botox is used in clinics without serious toxicity, the study indicates ...NCI Researchers Confirm the Effectiveness of Immunotherapy Approach to Treating Melanoma
...n the blood that can attack tumors, were separated from other parts of the blood. Next, patients were treated for two days with the chemotherapy agent cyclophosphamide followed by five days of fludarabine. The chemotherapy drugs were used to reduce the number of lymphocytes circulating in the blood, therefore reducin...Effective Cancer Treatments Follow The Clock
... in mice, the scientists found that the body's internal biological clock affects the survival of immune cells that are targets of the anti-cancer drug cyclophosphamide (CY). “We became interested in examining this issue because there is a long history of knowledge that chemotherapeutic agents produce different mor...Cyclophosphamide in Biological Technology
CALGARY, Jan. 7 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (TSX:
ONC, NASDAQ: ONCY) ('Oncolytics') reported today that a research group led
by Dr. Richard Vile of the Mayo Clinic College of Medicine in Rochester,
Minnesota, published the results of its work testing the antitumor efficacy...
CALGARY, Oct. 23 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced today that it has received a letter of approval from the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) for its Clinical Trial Application (CTA) to begin a clinica...
... Cardiac toxicity may also occur at lower cumulative doses (400 mg/m2) in patients with prior mediastinal irradiation or who are receiving concurrent cyclophosphamide therapy Acute infusion-related reactions including, but not limited to, flushing, shortness of breath, facial swelling, head...
...Survival (DFS) and Overall Survival (OS), compared to AC-T (doxorubicin and cyclophosphamide followed by docetaxel) and a 5-fold lower cardiotoxicity compared to AC-...-containing control regimen consisting of doxorubicin (A, 60 mg/m2) plus cyclophosphamide (C, 600 mg/m2) every three weeks for four cycles followed by Taxotere(R)...
...l 9735 at 2007 San Antonio Breast Cancer Symposium Showed Taxotere(R) and cyclophosphamide Improved Overall Survival Versus An Anthracycline Combination SAN ANT...emotherapy combination of Taxotere(R) (docetaxel) Injection Concentrate and cyclophosphamide significantly improved overall survival compared to standard chemotherapy. ...
CALGARY, Oct. 23 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced today that it has received a letter of approval from the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) for its Clinical Trial Application (CTA) to begin a clinica...
... Cardiac toxicity may also occur at lower cumulative doses (400 mg/m2) in patients with prior mediastinal irradiation or who are receiving concurrent cyclophosphamide therapy Acute infusion-related reactions including, but not limited to, flushing, shortness of breath, facial swelling, head...
Health Robotics Announces Results of the European Union-Sponsored SafeChemo Project
...ation has also been tested using cyclophosphamide. We were unable to detect cyclophosphamide above a detection limit of one picogram*/ml after having handled multiple cyclophosphamide doses in concentrations of 1g/50ml." Dr. Alicia Tavella, Oncology Ph...Oncolytics Biotech Inc. Announces 2008 Second Quarter Results
...er trial using systemic and intraperitoneal administration of REOLYSIN(R). - Started patient enrolment in a U.K. combination REOLYSIN(R) and cyclophosphamide trial. - Subsequent to the quarter end, announced that the 200th patient had been treated with REOLYSIN(R). Preclinical Advances - Two pres......Survival (DFS) and Overall Survival (OS), compared to AC-T (doxorubicin and cyclophosphamide followed by docetaxel) and a 5-fold lower cardiotoxicity compared to AC-...-containing control regimen consisting of doxorubicin (A, 60 mg/m2) plus cyclophosphamide (C, 600 mg/m2) every three weeks for four cycles followed by Taxotere(R)...
Oncolytics Biotech Inc. Announces 2008 First Quarter Results
...g the antitumor efficacy and safety of various combinations of reovirus and cyclophosphamide in vivo. The paper, entitled "Cyclophosphamide Facilitates Antitumor Effica...ties. The data support investigation in human clinical trials of the use of cyclophosphamide prior to systemic reovirus administration to modulate, but not ablate, the ...ProMetic presents preclinical data for prostate and pancreatic cancer at the AACR Meeting
...cancer both in vitro and in vivo. The in vivo study demonstrated a significant reduction in tumor volume both alone (p < 0.05) and in combination with cyclophosphamide (p < 0.01). Dr. Lyne Gagnon, ProMetic's Director of Research and Development, Biology, presented preclinical data on the PBI-0110 alone and in combi...Oncolytics Biotech Inc. Reports Highlights and Financial Results for 2007
... Drug Administration (FDA) to conduct a Phase II melanoma trial with REOLYSIN(R); - Approval to begin a Phase I combination REOLYSIN(R) and cyclophosphamide trial in the U.K.; - In January 2008, the NCI filed a protocol with the U.S. FDA to conduct a Phase I/II ovarian, peritoneal and fallopian tube......l 9735 at 2007 San Antonio Breast Cancer Symposium Showed Taxotere(R) and cyclophosphamide Improved Overall Survival Versus An Anthracycline Combination SAN ANT...emotherapy combination of Taxotere(R) (docetaxel) Injection Concentrate and cyclophosphamide significantly improved overall survival compared to standard chemotherapy. ...
Other TagsMechanicalTryingMonoclonalMonoclonalOsteoarthritisEncouragingInteractionInteractionInteractionSignalSignalSignalSignalLungsNeuronNeuronNeuronNeuronNeuronNobelNegativeNegativePreliminaryOther Contentsproductproductproductproductproductproductproductproductproductsilencingsilencingsilencingsilencingsilencingsilencingtargetingtargetingtargetingtargetingtargetingtargetingtargetingdiversitydiversitydiversitydiversitydiversitydiversityengineeringengineeringengineeringengineeringengineeringengineeringengineeringfingerprintfingerprintfingerprintfingerprintinteractionsinteractionsinteractionsinteractionsinteractionsinteractionsinteractionsinteractionsinteractions
MechanicalTryingMonoclonalOsteoarthritisGladstoneBackacheEncouragingInteractionSignalLungsNeuronNobelNegativePreliminary
(Date:11/25/2009)... that grew out of a collaboration between UCLA eng... to the nearly 10 million Americans who suffer fro...as hardening of the arteries, peripheral arterial ...n which narrowed arteries reduce blood flow to the... vascular disease, heart attack and stroke, and it...
(Date:11/25/2009)... was too short to draw definite conclusions, exper...ay News) -- In diabetic patients with blocked coro...n outcomes at one year whether patients undergo by... researchers report. , Bypass surgery has been ...coronary artery disease. However, less invasive ap...
(Date:11/25/2009)...Evaluation and treatment clinics to resume Monday,...us) November 25, 2009 -- Centegra Health System is...vaccine shots at four Centegra Primary Care (CPC) ...ine has arrived. The clinics are at CPC sites in H...ll be open as follows: , From 4:30 t...
(Date:11/25/2009)... neurological symptoms, study finds , ,...al side effects are among the potential problems f...ho were treated with cisplatin-based chemotherapy,...409 Norwegian men treated for unilateral testicula...follow-up survey conducted from 1998 to 2002. ,...
(Date:11/25/2009)...ewswire/-- MISSIONSkincare ®isproudtosupportG...rtofGNC,sannualSt.Jude ThanksandGiving campaign,$1... SUPER-C(TM)LipBalm willbedonatedtoSt.Jude.Additi...r$10donationatcheckoutatoneoftheir5,000+retailloca...orSt.Judeduringtheir2009 ThanksandGiving campaign....
Breaking Medicine News(10 mins):Health News:Engineers, doctors at UCLA develop novel material that could help fight arterial disease 2Health News:Engineers, doctors at UCLA develop novel material that could help fight arterial disease 3Health News:Engineers, doctors at UCLA develop novel material that could help fight arterial disease 4Health News:Stenting May Equal Bypass for Diabetic Heart Patients 2Health News:Stenting May Equal Bypass for Diabetic Heart Patients 3Health News:Centegra H1N1 Vaccination Clinics to Resume Tuesday, Dec. 1 2Health News:Centegra H1N1 Vaccination Clinics to Resume Tuesday, Dec. 1 3Health News:Centegra H1N1 Vaccination Clinics to Resume Tuesday, Dec. 1 4Health News:MISSION Skincare(R) Supports GNC's Efforts To Raise Money for St. Jude Children's Research Hospital(R) 2[1] Engineers, doctors at UCLA develop novel material that could help fight arterial disease[1] Stenting May Equal Bypass for Diabetic Heart Patients [0] Centegra H1N1 Vaccination Clinics to Resume Tuesday, Dec. 1[0] Long-Term Problems Linked to Testicular Cancer Chemo[2] MISSION Skincare(R) Supports GNC's Efforts To Raise Money for St. Jude Children's Research Hospital(R)
(Date:11/23/2009)..., 2009 - The time of day matters to forest trees d...uced by a research team led by Professor Malcolm C...principal for research and colleagues in the depar...e campus. , Capitalizing on their previous wor...earch team examined how poplar trees use their 45,...
(Date:11/23/2009)...t research suggests that a common oral bacterium m...ort by Nichols et al, "Unique Lipids from a Common...ands Capable of Enhancing Autoimmunity," appears i... of Pathology . , Multiple sclerosis (MS), a dis... spinal cord, affects nearly 1 in 700 people in th...
(Date:11/23/2009)... producing some of the highest resolution images o...ts have a deeper understanding how biomolecules ma...ad to a new treatment for kidney stones using biom...ov. 23 online edition of the journal Proceedings ... peptides interact with mineral surfaces by accele...
Breaking Biology News(10 mins):Time of day matters to thirsty trees, U of T researcher discovers 2Factors from common human bacteria may trigger multiple sclerosis 2Scientists watch as peptides control crystal growth with 'switches, throttles and brakes' 2Scientists watch as peptides control crystal growth with 'switches, throttles and brakes' 3Existing Drug May Lead to ALS Treatment 59797 1Existing Drug May Lead to ALS Treatment 59797 2Detailed Results from RV 144 HIV Vaccine Trial Published Today in The New England Journal of Medicine and Presented at the AIDS Vaccine 2009 Conferenc 59795 1Detailed Results from RV 144 HIV Vaccine Trial Published Today in The New England Journal of Medicine and Presented at the AIDS Vaccine 2009 Conferenc 59795 2Detailed Results from RV 144 HIV Vaccine Trial Published Today in The New England Journal of Medicine and Presented at the AIDS Vaccine 2009 Conferenc 59795 3Cardiac Science Expands into Vital Signs Market with Exclusive OMRON Healthcare Agreement 5585 1Cardiac Science Expands into Vital Signs Market with Exclusive OMRON Healthcare Agreement 5585 2Cardiac Science Expands into Vital Signs Market with Exclusive OMRON Healthcare Agreement 5585 3Cardiac Science Expands into Vital Signs Market with Exclusive OMRON Healthcare Agreement 5585 4Cardiac Science Expands into Vital Signs Market with Exclusive OMRON Healthcare Agreement 5585 5Cardiac Science Expands into Vital Signs Market with Exclusive OMRON Healthcare Agreement 5585 6| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |